Intellia Therapeutics
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
About
Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing curative therapeutics using its proprietary CRISPR/Cas9 technology. The company aims to precisely edit genes within the body to treat a range of severe diseases, including genetic disorders and cancer, offering potentially transformative treatments for patients. Teams look it up for Biotech, MedTech, Genomics.
Frequently asked
What does Intellia Therapeutics do?
Intellia Therapeutics is a Biotech company that offers Platform. Teams look it up for MedTech, Genomics, Drug Discovery. It is based in Cambridge, United States and was founded in 2014. Public records show $310M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Intellia Therapeutics raised?
Intellia Therapeutics has raised a total of $310M in funding. The most recent round on record is Series C.
Where is Intellia Therapeutics headquartered?
Intellia Therapeutics is headquartered in Cambridge, United States.
When was Intellia Therapeutics founded?
Intellia Therapeutics was founded in 2014.
What industry does Intellia Therapeutics operate in?
Intellia Therapeutics operates in Biotech, MedTech, Genomics, Drug Discovery, Clinical Trials.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.